糖尿病:药物基因组学指导治疗是否有未来?
本文综述了二甲双胍、磺脲类、噻唑烷二酮类和二肽基肽酶-4抑制剂的药物遗传学证据,指出这些变异仅在处方时已知基因型才有临床价值。糖尿病药物基因组学的未来依赖于先发面板基因分型和临床决策支持工具,将遗传信息与其他临床表型数据整合并简单呈现给处方者。
要点
- 单基因糖尿病中明确遗传病因可显著影响治疗,患者可从胰岛素转为磺脲类。
- 二甲双胍、磺脲类、噻唑烷二酮类和DPP-4抑制剂的药物遗传学证据已积累,但临床效用依赖于处方时已知基因型。
- 未来需先发面板基因分型和临床决策支持工具整合遗传与表型数据,简化呈现给处方者。
核心结论
- 糖尿病药物遗传学变异仅在处方时基因型已知才有临床效用,未来依赖先发基因分型和临床决策支持工具。
研究设计与样本
- 综述,未报告检索范围与样本量。
主要发现
- 单基因糖尿病中明确遗传病因可使患者从胰岛素转为磺脲类治疗。
- 多数糖尿病为2型糖尿病,二甲双胍、磺脲类、噻唑烷二酮类和DPP-4抑制剂的药物遗传学证据已积累。
临床怎么用
- 处方时已知基因型时,药物遗传学变异才可用于指导糖尿病治疗。
- 未来可借助先发面板基因分型和临床决策支持工具整合遗传信息与临床表型数据辅助处方。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diabetes is a disease defined on the basis of hyperglycemia. There are monogenic forms of diabetes where defining the genetic cause has a dramatic impact on treatment-with patients being able to transition from insulin to sulfonylureas. However, the majority of diabetes is type 2 diabetes. This review outlines the robust evidence accrued to date for pharmacogenetics of metformin, sulfonylureas, thiazolidinediones, and dipeptidyl peptidase-4 inhibitors but highlights that these variants will only be of clinical utility when the genotype is already known at the point of prescribing. The future of pharmacogenetics in diabetes and other common complex disease relies on a paradigm shift-that of preemptive panel genotyping and use of clinical decision support tools to assimilate this genetic information with other clinical phenotypic data and to present this information simply to the prescriber. Given the recent dramatic fall in genotyping costs, this future is not far off.
引用
- Pearson ER. Diabetes: Is There a Future for Pharmacogenomics Guided Treatment? Clin Pharmacol Ther. 2019. PMID: 31012484. doi:10.1002/cpt.1484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。